Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8986072 | 0.99 | MEN1 (0.73) | DHFRMEN1KMT2ANPC1CYP2D6 | |
| SCHEMBL671783 | 0.90 | DHFR (0.73) | DHFRMEN1KMT2ANPC1CYP2D6 | |
| Chlorcycloguanil SCHEMBL8986158 | 0.85 | DHFR (1.00) | DHFRMEN1KMT2ANPC1 | |
| SCHEMBL670498 | 0.82 | DHFR (0.79) | DHFRMEN1KMT2ANPC1 | |
| SCHEMBL669914 | 0.81 | DHFR (0.77) | DHFRMEN1KMT2ANPC1 | |
| SCHEMBL671428 | 0.81 | DHFR (0.77) | DHFRMEN1KMT2ANPC1 | |
| SCHEMBL671811 | 0.80 | NPSR1 (0.60) | DHFRMEN1KMT2ANPC1CYP2D6 | |
| SCHEMBL672643 | 0.80 | NPSR1 (0.60) | DHFRMEN1KMT2ANPC1CYP2D6 | |
| SCHEMBL18310350 | 0.80 | MEN1 (0.86) | DHFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL671587 | 0.79 | NPSR1 (0.66) | DHFRMEN1KMT2ANPC1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808464-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2017-11-07 | — | — | US | claimed |
| EP-2605804-B1 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | UNIV EMORY (US) | 2017-03-15 | — | — | EP | claimed |
| US-20170035771-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | claimed |
| US-9511071-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2016-12-06 | — | — | US | claimed |
| EP-2605804-A2 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | Emory University (US) | 2013-06-26 | — | — | EP | claimed |
| US-20130137634-A1 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-30 | — | — | US | claimed |
| WO-2012024489-A2 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-02-23 | — | — | WO | claimed |
| US-5565451-A | 1-substituted-2, 4-diamino-6, 6-dialkyl-1, 6-dihydro-1, 3, 5-triazines as insecticides | FMC CORPORATION (US) | 1996-10-15 | — | — | US | claimed |
| US-11844802-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230044670-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | UNIV EMORY (US) | 2023-02-09 | — | — | US | disclosed |
| US-11471461-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210100806-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | UNIV EMORY (US) | 2021-04-08 | — | — | US | disclosed |
| US-10888565-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200121687-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | UNIV EMORY (US) | 2020-04-23 | — | — | US | disclosed |
| EP-2605804-B1 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | UNIV EMORY (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170035771-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| US-9511071-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2605804-A2 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | Emory University (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130137634-A1 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2012024489-A2 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10888565-B2 | Compounds and compositions for ossification and methods related thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-20130137634-A1 | COMPOUNDS AND COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-11471461-B2 | Compounds and compositions for ossification and methods related thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-20230044670-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-20210100806-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-20170035771-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-20200121687-A1 | Compounds and Compositions for Ossification and Methods Related Thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
| US-11844802-B2 | Compounds and compositions for ossification and methods related thereto | BMP2, SOST, BMP4 | DHFR 3180/4885MEN1 1322/4885KMT2A 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.